Skip to main content
RYTM logo

RYTM · Rhythm Pharmaceuticals, Inc.

Track RYTM — free
$119.99 +0.95 (+0.80%)
Market Cap
$8.25B
Shares
69.33M
Volume · Nov 18 2.13M Avg daily vol (3M) 1.07M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$119.04 Open$115.72 Day$114.59–121.41 52W close$75.82–119.04 Avg vol 30d1.6M Short int11.7M · 16.8% of shares · 23.3d Short vol54% Last earningsNov 3, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Dec 24, 2026 Est · unconfirmed · in 5 wks

Latest documents

2026
Nov 11
Investor event
MCVRI launch exceeds 700 start forms

Rhythm reported over 700 MCVRI start forms for acquired hypothalamic obesity and said it remains self-sustaining without external capital. The company committed $350 million over four years to reduce BIVA-Mellagon royalties to 1% and plans a Prader-Willi study in 2027.

4 source passages
last week we reported over 700 start forms launched to date we do believe that RYTHM is self-sustaining and doesn't need external capital we committed to a fixed payment of $350 million over four years to buy down the BIVA-Mellagon royalty from somewhere in the 5% to 7% range to 1% flat hopefully get to starting of a hyperphagia-focused study in patients with PWS in 2027 Open the document at this passage
Nov 9
Investor event
AHO Launch Steady as $750 Million Debt Capacity Is Secured

Rhythm Pharmaceuticals said its AHO launch is maintaining a steady pace into the fourth quarter, it has $750 million of debt capacity with $250 million expected to be drawn, and it aims to start a Prader-Willi trial in early Q3.

5 source passages
So let's talk about AHO and the launch. we're into the fourth quarter now, and it's continuing to go at a steady pace here. The CEO and President and Chairman of Rhythm Pharmaceuticals, David Meeker. We have access to $750 million. We only need to draw down $250 million. starting a Prader-Willi trial mid-year, early Q3. Open the document at this passage
Nov 3
Earnings call
Acquired HO launch drove third-quarter sales to $92.1 million

Rhythm Pharmaceuticals reported global net product sales of $92.1 million in the third quarter, up 29% sequentially. More than 700 patient start forms were received, and the acquired HO therapy launched in Japan on October 14th.

3 source passages
Global net product sales of MSIVRI totaled $92.1 million, which represents 29% sequential growth over the second quarter. Since launch on March 19th and through the first two quarters, we have received more than 700 patient start forms for acquired HO, Including start forms for 71 clinical trial patients. We are very pleased to have launched IMC-RE4 acquired HO in Japan on October 14th, following approval by the Ministry of Health, Labor and Welfare, or MHLW, and inclusion on Japan's national health insurance drug price list. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
IMCIVREE sales rise 29% amid expanded financing

Rhythm reported third-quarter IMCIVREE global sales of $92.1 million, up 29% sequentially. A term loan provides up to $750 million, while an amended bivamelagon license requires $350 million in fixed payments over four years.

Revenue $92.13M ▲ 79.6% Net loss $41.37M Diluted EPS -$0.61
Read from the MD&A section
3 source passages
Revenue from global sales of IMCIVREE was $92.1 million for the third quarter of 2026, an increase of 29% on a sequential basis from the second quarter of 2026. On November 2, 2026, we announced the Company entered into a five-year term loan facility led by KKR's HealthCare Royalty in partnership with Blackstone, providing access to up to $750 million of capital. On November 2, 2026, we announced an amendment to our exclusive license agreement with LG Chem for bivamelagon. Under the terms of the amendment, Rhythm has agreed to pay LG Chem $350 million in fixed payments over four years in order to reduce the low-to-mid single digit royalty in the original agreement to 1% royalty on net product revenue generated by Rhythm’s MC4R portfolio; Open the document at this passage
Nov 3
Current report 8-K
IMCIVREE revenue rises 29% sequentially

Rhythm Pharmaceuticals reported IMCIVREE revenue of $92.1 million, up 29% sequentially, and more than 700 patient start forms. Net loss attributable to common stockholders was $(42.4) million; a five-year term loan provides access to up to $750 million.

Financial results
5 source passages
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2026. Revenue from global sales of IMCIVREE was $92.1 million for the third quarter of 2026, an increase of 29% on a sequential basis from the second quarter of 2026. Today, the Company announced it has received more than 700 patient start forms for IMCIVREE for acquired HO from more than 500 prescribers as of September 30, 2026, following approval by the U.S. Food and Drug Administration (FDA) on March 19, 2026; Net loss attributable to common stockholders was $(42.4) million for the third quarter of 2026, or a net loss per basic and diluted share of $(0.61), as compared to a net loss attributable to common stockholders of $(54.3) million for the third quarter of 2025, or a net loss per basic and diluted share of $(0.82). On November 2, 2026, the Company entered into a five-year term loan facility led by KKR's HealthCare Royalty ("Healthcare Royalty") in partnership with Blackstone Life Sciences, providing access to up to $750 million of capital. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$280.75M
Trailing 12 months
Net income (TTM)
−$193.81M
Trailing 12 months
Revenue growth YoY
+79.6%
Year over year
Operating margin
-66.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$218.28M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.2%
Year over year · more shares
Price change (1Y)
+18.4%
Trailing year
Short interest
16.8%
Latest settlement · 23.3 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. Rhythm delivered 29% sequential product-revenue growth, sustained U.S. launch momentum, launched IMCIVREE in Japan, advanced bivamelagon into pivotal development, reduced the portfolio royalty to 1%, and expects at least 24 months of operating funding. The company remained loss-making as R&D and SG&A increased, while Japan's initial two-week supply restriction may constrain launch uptake.

Bullish
  • + Q3 global IMCIVREE product revenue reached $92.1 million, increasing 29% sequentially.
  • + The U.S. acquired-HO launch exceeded 700 patient start forms from more than 500 prescribers.
  • + The commercial launch of IMCIVREE for acquired HO in Japan began on October 13, 2026.
  • + Bivamelagon is advancing into pivotal trials in both acquired HO and Prader-Willi syndrome.
  • + The amended bivamelagon license reduces the MC4R portfolio royalty to 1% of net product revenue.
  • + Management expects available cash and investments to fund planned operations for at least 24 months.
Bearish
  • − Rhythm reported a Q3 net loss attributable to common stockholders of $42.4 million, or $0.61 per share.
  • − Q3 R&D expenses increased year over year, primarily because of CMC activity, clinical-trial and personnel costs, and a congenital hyperinsulinism milestone.
  • − Q3 SG&A expenses increased year over year, primarily because of higher personnel costs tied to expanded operations.
  • − Japan's first-year launch restricts prescriptions to two-week supply and requires hospital consultations every two weeks.
  • − Rhythm must pay LG Chem $350 million in fixed payments over four years, beginning with $70 million due 15 days from closing.
  • − Cash, cash equivalents and short-term investments declined from $388.9 million at December 31, 2025 to approximately $320.9 million at September 30, 2026.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +22%
above
Price vs 50-day avg +22%
above
RSI (14) 65
neutral
MACD trend Positive
52-week position 100%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +34%
trailing
6-month return +35%
trailing
YTD return +11%
this year
Relative strength +38%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) Golden cross
50d $98 › 200d $97 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +56 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.84% of shares out · ▲ +6.1% MoM · 23.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
335 holders — near 3-yr high, broad support
Squeeze score 89
high risk · 0–100
Fundamentals
Fair
EPS growth +28%
Y/Y
Free cash flow $-116.6M
Balance sheet $53.9M
net debt
Quant / Vol
risk profile
Very High
Volatility 56%
annualized · 1-yr
Max drawdown −36%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 3, 2026
Non-GAAP Operating Expenses · for the year ending December 31, 2026 Non-GAAP Lowered $360M – $380M
Aug 4, 2026 $363M – $397M changed to Nov 3, 2026 $360M – $380M
Previous outlook earlier release · from the Earnings Call filed Aug 4, 2026

Still-open targets the latest release did not restate under the same label.

Non-GAAP SG&A expenses · 2026 $188M – $202M
Non-GAAP R&D expenses · 2026 $175M – $195M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 2 · 5
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+22% Bullish
Price vs 50-day avg
+22% Bullish
RSI (14)
65 Neutral
MACD trend
Positive Bullish
52-week position
100% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) Golden cross
50d $98 › 200d $97 — 50d above 200d
Institutional flow Accumulating
+8% holders QoQ · +56 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
16.84% of shares out · ▲ +6.1% MoM · 23.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
335 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $76 Now $119 · 100% Range high $119
vs 200-day avg +22% vs 50-day avg +22% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adult Endocrinologist share of prescribers 43% Between FDA approval on March 19, 2026 and June 30, 2026 —
Cash, cash equivalents and short-term investments $330.9M as of June 30, 2026 —
Commercial covered lives with positive policies 35% Between FDA approval on March 19, 2026 and June 30, 2026 —
Ex-U.S. revenue $20.3M second quarter of 2026 —
Ex-U.S. share of product revenue 28% the second quarter of 2026 filing —
Increase in number of patients globally on reimbursed therapy 20% Q2 2026 —
Mean BMI reduction from baseline with RM-718 (n=7) at 16 weeks 11.6% after 16 weeks of treatment —
Medicaid covered lives with positive policies 25% Between FDA approval on March 19, 2026 and June 30, 2026 —
Patient start forms since FDA approval 400 as of June 30, 2026 —
Pediatric Endocrinologist share of prescribers 37% Between FDA approval on March 19, 2026 and June 30, 2026 —
Prescribers activated 65% Between FDA approval on March 19, 2026 and June 30, 2026 —
Repeat aHO prescribers 20% Between FDA approval on March 19, 2026 and June 30, 2026 —
revenue generated from a single customer in the United States 72% the three months ended June 30, 2026 filing —
Sequential increase in IMCIVREE global sales 19% Q2 2026 —
Share of prescriptions from priority accounts 25% Between FDA approval on March 19, 2026 and June 30, 2026 —
Share of Q2 2026 revenue from U.S. 72% Q2 2026 —
U.S. revenue $51M second quarter of 2026 —
Unique prescribers 300 Between FDA approval on March 19, 2026 and June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RYTM
Rhythm Pharmaceuticals, Inc.
this stock
$8.25B +11.2% +45.8% — 16.8%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
335
% held
114.0%
Net QoQ
+1.8M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
346
View
Short & Settlement
Short Interest Rising
Shares short
11.7M
Days to cover
23.3d
Change
+672.0K sh
View
Short Volume
Short vol %
54%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
5.3K
Value
$462.6K
As of
Oct 15, 2026
View
Off-Exchange
Off-exchange %
47.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$189.8M
Net income (FY)
$-196.5M
EPS diluted
$-3.11
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 11, 2026
This year
29

Rhythm reported over 700 MCVRI start forms for acquired hypothalamic obesity and said it remains self-sustaining without external capital. The company committed $350 million over four years to reduce BIVA-Mellagon royalties to 1% and plans a Prader-Willi study in 2027.

View
Proposed Sales
Value
$5.4M
Shares
45.9K
Filed
Nov 18, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
Rhythm Pharmaceuticals Reports Th…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
RYTM +6.1% +34.3% +34.8% +28.6% +11.2%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY +10.0% +39.9% +38.3% +32.0% +4.1%
Key facts CIK 1649904 CUSIP 76243J105 13F (30d) 353 filings 315 filers Visit website Investor relations